Stephen Liu
MD
Chief of Hematology and Oncology
Georgetown University
Jun 05, 2026
Episode
365
Soundcloud
Share
In this Part 1 ASCO 2026 Highlights episode, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Alice Shaw and Dr. Jonathan Goldman to review some of the most impactful targeted therapy data presented at the 2026 ASCO Annual Meeting. The discussion explores the practice-changing LIBRETTO-432 trial in early-stage RET-positive NSCLC, long-term outcomes with lorlatinib in ALK-positive disease, emerging data for neladalkib, and promising results for sunvozertinib in EGFR exon 20 insertion–positive NSCLC, highlighting how these findings may influence treatment decisions across disease stages.
Guest
Narjust Florez
MD
Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Jonathan Goldman
MD
Professor of Medicine, Director of Clinical Trials in Thoracic Oncology & Associate Director of Drug Development
UCLA Hematology & Oncology
Alice Shaw
MD, PhD
Chair, Department of Medical Oncology
Dana Farber Cancer Institute
George P. and Jean S. Canellos Professor of Medicine, Harvard Medical School
